![https://hotcopper.com.au/data/attachments/3619/3619853-116e4f816caec786388eb0e4e5c1c9b7.jpg](https://hotcopper.com.au/data/attachments/3619/3619853-116e4f816caec786388eb0e4e5c1c9b7.jpg)
Analysts from investment firms have been steadily increasing their coverage of the psychedelic space, from Cybin receiving several positive reports to Compass getting a strong Buy rating, to the Maxim Group initiating coverage on ten shroom stocks.
Eight Capital Gives Buy Rating to 6 Shroom Stocks
Eight Capital analyst Sepehr Manochehry led the coverage, focusing on 6 psychedelic firms. The firm published an industry report a few months ago, giving their clients a review of the industry; and now, according to the analyst:
MindMed
Current price: $3.10
Target price: $6.50
Cybin
Current price: $2.76
Target price: $8.15
Click to View ArticleAs per ASX anouncement on 11th Feb, 2021
The predominant purpose of the consulting arrangement is for EAS to facilitate introductions to US banks
and institutions with the aim of dual listing IHL securities on a US main market, such as the NYSE or Nasdaq,
whilst simultaneously retaining an ASX listing.
The scope of work also includes the following:
•
Introductions to equity research providers in order to secure analyst coverage• To generate global investor awareness with potential strategic investors in the USA, Europe, Asia,
and Australia
• To assist with financial modelling, presentation preparation and external data room maintenance.
For this reason I am looking forward to seeing similar Broker coverage for IHL, very soon
Good luck all
![wink.png](https://hotcopper.com.au/images/smilies/wink.png)